How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signaling in Parkinson disease

neurodegeneration partially_addressed
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
—
Novelty
—
Mechanistic
—
Druggability
—
Priority
90%
Importance
—
Tractability
—
Market price
50%

Description

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclein aggregation and dopaminergic neuron survival via vagal nerve signaling in Parkinson disease

Resolution criteria

Resolved when: a cited mechanistic map shows how SCFAs, LPS, and TMAO affect alpha-synuclein aggregation and dopaminergic neuron survival through vagal, immune, barrier, or metabolic signaling in Parkinson disease models. Required deliverables are KG edges for metabolite, pathway, cell/region target, and phenotype, plus a scored hypothesis or debate synthesis distinguishing direct metabolite effects from microbiome confounding.